Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0A6DI
|
||||
| Former ID |
DIB003993
|
||||
| Drug Name |
RG-1662
|
||||
| Synonyms |
GABA-A agonist (Alzheimer's disease), Roche
|
||||
| Indication | Alzheimer disease [ICD9: 331; ICD10:G30] | Phase 2 | [1] | ||
| Company |
Roche Holding AG
|
||||
| Structure |
|
Download2D MOL |
|||
| Target and Pathway | |||||
| Target(s) | Gamma-aminobutyric-acid receptor alpha-5 subunit | Target Info | Agonist | [2] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Retrograde endocannabinoid signaling | |||||
| GABAergic synapse | |||||
| Morphine addiction | |||||
| Nicotine addiction | |||||
| Reactome | Ligand-gated ion channel transport | ||||
| GABA A receptor activation | |||||
| WikiPathways | Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | ||||
| Iron uptake and transport | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT02484703) A Study of RG1662 in Down Syndrome Among Children 6 to 11 Years of Age. | ||||
| REF 2 | RG1662, a Selective GABAA alpha5 Receptor Negative Allosteric Modulator, Increases Gamma Power in Young Adults with Down Syndrome. Neurology April 6, 2015 vol. 84 no. 14. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.